Cost-effectiveness analysis of gastric cancer screening in Japan was performed, and the cost-effectiveness ratio was compared with that of colorectal cancer screening. The analytical model was the same as that adopted in our previous study on colorectal cancer screening (Tsuji et al. 1991). The results indicated that the cost per case-fatality prevented by colorectal cancer screening was 5.5 and 2.7 times more expensive for males and females, respectively, than that by gastric cancer screening. The age of the population influenced the cost-effectiveness of screening programs. The costeffectiveness ratio in gastric cancer screening became negative among males older than the age of 65 years, suggesting that the total cost for prevention and control of deaths by gastric cancer in these age populations is saved by the screening program.
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cost-effectiveness analysis ; gastric cancer screening ; simulation study Our previous cost-effectiveness analysis on colorectal cancer screening (Tsuji et al. 1991) showed that the combination of the two-day immunological fecal occult blood test (FOBT) and total colonoscopy (TCF) was the best cost-effective strategy in Japan. The cost per life-year saved by this screening method amounted 3,308.5 (x 103) yen for males and 4,130.3 (x 103) yen for females.
These findings lead us to question whether or not a public financed program for colorectal cancer screening should be initiated, and whether the program would be economically worthy of sponsoring. Unlike a cost-benefit analysis, a costeffectiveness analysis does not judge the "absolute" value of a program, but provides information on its "relative" value in comparison with other programs. Therefore, to answer the above questions, it is necessary to compare the cost-effectiveness ratio of colorectal screening with that of other preventive programs for the same cancer or with that of screening for other cancers.
The objective of the present study is to compare the cost-effectiveness ratio of colorectal cancer screening with other cancer screening program in Japan. For this purpose, we chose a screening for gastric cancer as the control since it has been widely employed in this country.
Cost-effectiveness analyses on gastric cancer screening have already been extensively studied in Japan (Hisamichi et al. 1976; Sugawara et al. 1982; Iinuma and Tateno 1988a, 1990; Sugawara and Hisamichi 1987) . However, since the cost-effectiveness ratios are highly sensitive to the analytical models, we performed a cost-effectiveness analysis on gastric cancer screening and compared it with colorectal cancer screening by the same analytical model.
METHODS
We performed a cost-effectiveness analysis on gastric cancer screening in Japan according to our model previously used for colorectal cancer. The model and the methods to estimate the cost and effectiveness of programs were described by our previous study in detail (Tsuji et al. 1991) . The data on 5-year survival rates and cost for treating the detected cases were available from a screening program and a hospital, respectively. Thus, it was unnecessary to estimate the distribution of cancer stages among the population.
In the present screening program, we first screened the population applying indirect gastrofluorography, and if any suspicious findings were present, we utilized direct gastrofluorography, gastroscopy, and/or tissue biopsy, as indicated.
Data resource
Incidence rate of gastric cancer. The estimated sex-and age-specific incidence rates in Japan in 1985 (Research Group for Population-based Cancer Registration in Japan 1990).
Mortality rates of gastric cancer and other causes. Vital Statistics in Japan in 1985. Five-year survival rate of gastric cancer cases. Report on the annual survival rate of gastric cancer patients detected in a screening program and at a hospital, respectively .
Life expectancy. The 16th Life Tables in Japan in 1985. Efficacy of diagnostic tests. The sensitivity of indirect gastrofluorography was estimated to be 90.1% and its specificity to be 82.9%, according to the report of Hisamichi et al. (1978) . Both sensitivity and specificity of workup exams were assumed to be 100%.
Probability of complication due to gastroscopy. This value was estimated to be 0.001% according to the report of Namiki (1984) .
Costs for screening and diagnosis. The present charges at the Cancer Detection Center, Miyagi Cancer Association. The screening test costs 4,600 yen. The cost of workup exam was estimated to be 14,500 yen, based on the weighed average of the following three procedures. In the above center, direct gastrofluorography (14,570 yen) was performed on 18.1% of the workup examines, gastroscopy (11,930 yen) on 90.3%, and biopsy (10,160 yen) on 10.2%. Accordingly, the estimated cost for workup exam was 14,500 (14,570 x 0.181 + 11,930 x 0.903 + 10,160 x 0.102) yen.
We assumed that the diagnostic procedure at hospitals for the "no screen" cases and the false-negative cases at a screening would include direct gastrofluorography, gastroscopy, and tissue biopsy. Thus, the cost was estimated to be 45,000 yen, summing the examination fee and the others such as doctor fees.
Costs for medical treatment. Sugawara and Hisamichi (1987) reported the cost to be of Gastric Screening 281 1,242,000 yen for the cases detected at a screening, and 2,428,000 yen for those at a hospital. Table 1 shows the estimated cost and effectiveness of "no screen" and the screening program for males and females, respectively. Costs for diagnosis and treatment for gastric cancer remarkably decreased in the screening program. The cost for cancer-fatality prevented was calculated to be 1,975.3 (x 103) yen for males and 6,151.1 (x 103) yen for females. The cost for colorectal cancer screening (Tsuji et al. 1991) was 5.1 times greater in males and 2.3 times higher in Cost per life-year saved by colorectal and gastric cancer screening females than that for gastric cancer screening. The cost for life-year saved amounted 606.3 (X 103) yen for males and 1542.5 (X 103) yen for females. This cost of colorectal cancer screening was 5.5 and 2.7 times more expensive than that of gastric cancer screening in males and females, respectively.
RESULTS
In order to examine the effect of age on the efficiency of screening programs, we analyzed the cost-effectiveness according to a 5-year age class for both screenings with no discount. The costs for life-year saved are presented in Table 2 . For both sexes, the cost differences between the two increased with age. In gastric cancer screening, the cost-effectiveness ratio changed into a negative value among males from the age of 65 years. Accordingly, the total cost of the screening program is less than that of "no screen". It is suggested that the total cost for prevention and control of deaths by gastric cancer is saved by the screening program.
DISCUSSION
Economic appraisal on gastric cancer screening has been extensively conducted in Japan (Hisamichi et al. 1976 ; Iinuma and Tateno 1988a, 1990 ; Sugawara et al. 1982 ; Sugawara and Hisamichi 1987) . These studies favor the screening, based on data showing extensive economic benefit (Hisamichi et al. 1976 ), saving in medical expenditure (Sugawara and Hisamichi 1987) , and so forth. The present analysis is consistent with these studies.
The cost-effectiveness ratios of colorectal cancer screening were more than 5 times higher among males and more than 2 times greater among females than those of gastric cancer screening. This difference is mostly attributable to the difference in incidence between the two cancers. The incidence of gastric cancer was 2.84 times higher than that of colorectal cancer among males, and 1.96 times greater among females (Research Group for Population-based Cancer Registration in Japan 1990). Other factors for the difference include natural courses, costs, etc. This is the point to consider whether this difference of cost-effectiveness ratio is acceptable, or whether colorectal cancer as a public program is economically justifiable. According to Iinuma and Tateno (1988a, b, 1990 ) and Iinuma (1989) who compared the cost-effectiveness ratios among the various cancer screenings, ratio of lung cancer was about 10 times more expensive than that of gastric cancer screening for both sexes (Iinuma and Tateno 1988b) . Similarly, that of uterus was 0.88 times, and that of breast was 1.71 times greater than that of gastric cancer screening for females (Iinuma 1989) . Considering their results and ours altogether, the cost-effectiveness ratio of colorectal cancer screening is located amidst the cancer screening programs which are currently subsidized by the national government under the Geriatric Health Law. Thus, the cost-effectiveness ratio of colorectal cancer screening is within the acceptable range as a public policy.
It should be noted that the difference of the cost-effectiveness ratios between gastric and colorectal cancer screenings are sensitive to the following factors.
First, the future trend of the incidence of both cancers is different. Inawashiro et al. (1990) predicted that the incidence of colorectal cancer for both sexes in the year 2000 will be 2.95 times higher than that in 1980 while that of gastric cancer will be only 1.53 times greater, and the differences in the incidences between these cancers will decrease. Thus, the difference of the cost-effectiveness ratio between the two cancer screenings is expected to lower in the future. Second, one merit of the colorectal cancer screening lies in the quality as well as quantity of the surviving patients. The early detection of the lesion by screening saves some patients from the life-long burden of artificial anus which handicap their quality of life. If we incorporate this value into effectiveness in terms of a quality adjusted life-year as proposed by Weinstein and Stason (1977) , the difference in the cost-effectiveness ratios between the two cancer screening programs becomes much smaller. These factors support the potential utility of colorectal cancer screening, and it is concluded that colorectal cancer screening is economically justifiable as a public program.
